UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Harm reduction as treatment for Black and Hispanic individuals: response to Scheidell et al

The American journal of drug and alcohol abuse, 2024-05, Vol.50 (3), p.428-429

2024

Volltextzugriff (PDF)

Mediating effect of craving on the impact of buprenorphine/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial

Addictive behaviors, 2024-07, Vol.154, p.108023, Article 108023

2024

Volltextzugriff (PDF)

The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women

Journal of psychopharmacology (Oxford), 2018-12, Vol.32 (12), p.1385-1391

2018

Volltextzugriff (PDF)

Frequent Cannabis Use and Cessation of Injection of Opioids, Vancouver, Canada, 2005-2018

American journal of public health (1971), 2020-10, Vol.110 (10), p.1553-1560

2020

Volltextzugriff (PDF)

Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial

Drug and alcohol dependence, 2023-07, Vol.248, p.109932-109932, Article 109932

2023

Volltextzugriff (PDF)

The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada

Addiction (Abingdon, England), 2020-08, Vol.115 (8), p.1482-1493

2020

Volltextzugriff (PDF)

Does This Patient Have Alcohol Use Disorder?: The Rational Clinical Examination Systematic Review

JAMA : the journal of the American Medical Association, 2024-04, Vol.331 (14), p.1215

2024

Volltextzugriff (PDF)

Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis

The International journal of drug policy, 2023-08, Vol.118, p.104075-104075, Article 104075

2023

Volltextzugriff (PDF)

Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial

Drug and alcohol dependence, 2022-10, Vol.239, p.109604, Article 109604

2022

Volltextzugriff (PDF)

The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial

Canadian journal of psychiatry, 2024-03, Vol.69 (3), p.172-182

2024

Volltextzugriff (PDF)

The Veterans Aging Cohort Study (VACS) Index Predicts Mortality in a Community-recruited Cohort of People With Human Immunodeficiency Virus (HIV) Who Use Illicit Drugs

Clinical infectious diseases, 2021-08, Vol.73 (3), p.538-541

2021

Volltextzugriff (PDF)

Housing First: A housing model rooted in harm reduction with potential to transform health care access for highly marginalized Canadians

Canadian family physician, 2021-07, Vol.67 (7), p.481-483

2021

Volltextzugriff (PDF)

Opioid use and COVID-19: a secondary analysis of the impact of relaxation of methadone take-home dosing guidelines on use of illicit opioids

The American journal of drug and alcohol abuse, 2023-09, Vol.ahead-of-print (ahead-of-print), p.1-9

2023

Volltextzugriff (PDF)

Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial

The American journal of psychiatry, 2022-10, Vol.179 (10), p.726-739

2022

Volltextzugriff (PDF)

Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial

Canadian journal of psychiatry, 2023-08, Vol.68 (8), p.572-585

2023

Volltextzugriff (PDF)

Periods of Homelessness Linked to Higher VACS Index Among HIV-Positive People Who Use Drugs

AIDS and behavior, 2022-06, Vol.26 (6), p.1739-1749

2022

Volltextzugriff (PDF)

Canadian family physician Medecin de famille canadien

Canadian family physician, 2021-07, Vol.67 (7), p.e154-e156

2021

Volltextzugriff (PDF)

Trajectories of Retention in Opioid Agonist Therapy and Overdose Risk During a Community-Wide Overdose Epidemic in a Canadian Setting

American journal of preventive medicine, 2021-01, Vol.60 (1), p.57-63

2021

Volltextzugriff (PDF)

Substance Use and Adherence to Antiretroviral Therapy: What Is Known and What Is Unknown

Current infectious disease reports, 2018-09, Vol.20 (9), p.36-6, Article 36

2018

Volltextzugriff (PDF)

Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone

Clinical pharmacology and therapeutics, 2024-03, Vol.115 (3), p.506-514

2024

Volltextzugriff (PDF)

Associations of methadone and buprenorphine‐naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription‐type opioid use disorders: Exploratory analyses of the OPTIMA study

The American journal on addictions, 2023-09, Vol.32 (5), p.469-478

2023

Volltextzugriff (PDF)

The tripping point: The potential role of psychedelic-assisted therapy in the response to the opioid crisis

The International journal of drug policy, 2019-04, Vol.66, p.80-81

2019

Volltextzugriff (PDF)

Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report

Journal of psychoactive drugs, 2016-07, Vol.48 (3), p.214-217

2016

Volltextzugriff (PDF)

Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting

The International journal of drug policy, 2022-02, Vol.100, p.103518-103518, Article 103518

2022

Volltextzugriff (PDF)

Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder

Drug and alcohol dependence, 2023-06, Vol.247, p.109893-109893, Article 109893

2023

Volltextzugriff (PDF)

1 – 25 von 521

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(435)
Mit Volltextzugriff
(394)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

Harm reduction as treatment for Black and Hispanic individuals: response to Scheidell et al

Mediating effect of craving on the impact of buprenorphine/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial

The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women

Frequent Cannabis Use and Cessation of Injection of Opioids, Vancouver, Canada, 2005-2018

Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial

The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada

Does This Patient Have Alcohol Use Disorder?: The Rational Clinical Examination Systematic Review

Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis

Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial

The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial

The Veterans Aging Cohort Study (VACS) Index Predicts Mortality in a Community-recruited Cohort of People With Human Immunodeficiency Virus (HIV) Who Use Illicit Drugs

Housing First: A housing model rooted in harm reduction with potential to transform health care access for highly marginalized Canadians

Opioid use and COVID-19: a secondary analysis of the impact of relaxation of methadone take-home dosing guidelines on use of illicit opioids

Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial

Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial

Periods of Homelessness Linked to Higher VACS Index Among HIV-Positive People Who Use Drugs

Canadian family physician Medecin de famille canadien

Trajectories of Retention in Opioid Agonist Therapy and Overdose Risk During a Community-Wide Overdose Epidemic in a Canadian Setting

Substance Use and Adherence to Antiretroviral Therapy: What Is Known and What Is Unknown

Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone

Associations of methadone and buprenorphine‐naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription‐type opioid use disorders: Exploratory analyses of the OPTIMA study

The tripping point: The potential role of psychedelic-assisted therapy in the response to the opioid crisis

Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report

Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting

Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder

Suchergebnisse filtern